Dipraglurant - Addex Therapeutics

Drug Profile

Dipraglurant - Addex Therapeutics

Alternative Names: ADX 48621; Dipraglurant-ER; Dipraglurant-IR

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Addex Pharmaceuticals
  • Developer Addex Therapeutics
  • Class Alkynes; Antidepressants; Heterocyclic bicyclo compounds; Imidazoles; Muscle relaxants; Neuropsychotherapeutics; Pyridines; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 5 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Drug-induced dyskinesia; Torticollis
  • Preclinical Major depressive disorder
  • No development reported Dystonia
  • Discontinued Anxiety disorders

Most Recent Events

  • 28 Sep 2018 Addex Therapeutics plans registrational studies for dipraglurant in second half 2019
  • 28 Sep 2018 No recent reports of development identified for phase-I development in Dystonia in Switzerland (PO)
  • 03 Aug 2017 Phase-II clinical trials in Torticollis in Switzerland (PO) (Addex Therapeutics pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top